MediciNova, Inc. (MNOV)
- Previous Close
1.3300 - Open
1.3300 - Bid 0.9576 x 200
- Ask 1.7000 x 200
- Day's Range
1.3200 - 1.3900 - 52 Week Range
1.2600 - 2.6600 - Volume
8,026 - Avg. Volume
51,301 - Market Cap (intraday)
66.458M - Beta (5Y Monthly) 0.69
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1700 - Earnings Date May 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
17.00
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
www.medicinova.comRecent News: MNOV
Performance Overview: MNOV
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MNOV
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MNOV
Valuation Measures
Market Cap
66.46M
Enterprise Value
15.67M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
66.46
Price/Book (mrq)
1.07
Enterprise Value/Revenue
15.67
Enterprise Value/EBITDA
-1.59
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-8.81%
Return on Equity (ttm)
-12.93%
Revenue (ttm)
1M
Net Income Avi to Common (ttm)
-8.57M
Diluted EPS (ttm)
-0.1700
Balance Sheet and Cash Flow
Total Cash (mrq)
51M
Total Debt/Equity (mrq)
1.00%
Levered Free Cash Flow (ttm)
-5.12M